Search
GFT14
go.drugbank.com/drugs/DB05061ExperimentalGFT14 is a new class of medicaction for treatment of cardiometabolic disease. … GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides
Ditekiren
go.drugbank.com/drugs/DB19992ExperimentalDitekiren is a small molecule drug. The usage of the INN stem '-kiren' in the name indicates that Ditekiren is a renin inhibitor. Ditekiren has a monoisotopic molecular weight of 929.57 Da.
Categories: Agents Acting on the Renin-Angiotensin SystemImidurea
go.drugbank.com/drugs/DB14075ApprovedImidurea is an antimicrobial preservative used in cosmetics. It acts as a formaldehyde releaser.
Iocarmic acid
go.drugbank.com/drugs/DB13755ExperimentalCategories: Compounds used in a research, industrial, or household settingTreamid
go.drugbank.com/drugs/DB16365InvestigationalIt is has been investigated in the clinical trials of NCT04428593 (Study to Assess Safety, Tolerability and Pharmacokinetics of Treamid in Healthy Volunteers) and NCT04527354 (Pilot Study to Assess Efficacy … and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia) by PHARMENTERPRISES.
Methscopolamine bromide
go.drugbank.com/drugs/DB00462ApprovedA muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.
Synonyms: N-methylhyoscine bromide, N-methylscopolammonium bromidePirenzepine
go.drugbank.com/drugs/DB00670ApprovedWithdrawnIt promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. … It also potentiates the effect of other antiulcer agents such as cimetidine and ranitidine. It is generally well tolerated by patients.
International brands: PinTridolgosir
go.drugbank.com/drugs/DB02034ExperimentalAn indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.
Irofulven
go.drugbank.com/drugs/DB05786InvestigationalMGI-114 (Irofulven) is currently being developed by MGI PHARMA, Inc., an emerging oncology-focused pharmaceutical company based in Minneapolis. … Phase III clinical trials involving the drug have been underway since early 2001 at sites in the U.S. and Europe.
EGEN-001
go.drugbank.com/drugs/DB05953InvestigationalEGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity